Who We Are

Partnerships

To advance innovation and our mission to help oncology patients, we collaborate with other industry-leading biotechnology, pharmaceutical, and emerging biotech companies.

Natasha Hernday

Executive Vice President of Corporate Development

In it for life, together

Our partnerships focus on:

  • Innovative in-licensing opportunities at all development stages to diversify and grow our emerging global portfolio
  • Clinical and research collaborations that broaden the potential of our internal programs
  • Novel platform technologies that synergize with or expand our antibody–drug conjugate (ADC) capabilities in new and unique ways

Connect with us

To explore partnership opportunities, please contact businessdevelopment@seagen.com.

Our team

Seagen corporate development team

Steven Bartz

Vice President, Corporate Development

Seagen corporate development team

Emilie Coueignoux Chen

Sr. Director, Corporate Development

Seagen corporate development team

Roland Gendron

Sr. Director, Corporate Development

Seagen corporate development team

Wesley Galamb

Sr. Director, Corporate Development

Seagen corporate development team

Kelly Callahan

Sr. Manager, Corporate Development

Seagen corporate development team

Natasha Balakrishna

Sr. Manager, Corporate Development


Our co-development and commercial partners

Seagen collaborator Astellas
Seagen collaborator Genmab
Seagen collaborator Merck
Seagen collaborator Takeda

Our clinical collaborators

Seagen collaborator Bristol Myers Squibb
Seagen collaborator Genentech
Seagen collaborator Merck

Our ADC technology collaborators

Seagen collaborator Abbvie
Seagen collaborator Genentech
Seagen collaborator Genmab
Seagen collaborator GlaxoSmithKline
Seagen collaborator Lantheus